Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to Interleukin-17F (IL-17F) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IL-17F in human serum and plasma.
Interleukin 17F is a member of the IL-17 family, which includes 6 members (IL-17A, B, C, D, E, and F). IL-17F shares ~50% homology to IL-17A, is co-expressed with IL-17A, and is also produced often along with IL-17A primarily by T cell helper type 17 cells. Additionally, IL-17F can be secreted as a homodimer or a heterodimer with IL-17A. Homodimers or heterodimers of IL-17F signals through the same receptor (IL-17RA/RC), which is expressed primarily on non-hematopoietic cells. IL-17F has been correlated with all diseases that IL-17A has been implicated as a main pathogenic factor. These include inflammation due to autoimmune diseases, rheumatic diseases, certain cancers, and transplant rejection.
While most studies demonstrate that IL-17A is more potent compared to IL-17F, it has become clear that the activity of IL-17F is synergistic with IL-17A in various autoimmune diseases. Clinical studies have repeatedly demonstrated that blockage of both IL-17A and IL-17F is most effective at improving disease activity and/or progression. IL-17F is believed to play a bigger role in mucosal immunity. For airway inflammation that is dominated by neutrophils, such as neutrophilic severe asthma, IL-17 concentration in airway fluids correlates with neutrophil numbers, suggesting a more pathological role for IL-17F compared to IL-17A. RBM’s IL-17F Simoa assay can be a value tool in clinical studies to delineate a role for IL-17F.
Swiss-Prot Accession Number: Q96PD4
Alternate names for this biomarker include:
IL-17F, Cytokine ML-1
(Serum and Plasma)
|Serum or plasma||Other fluids**|
|Interleukin-17F (IL-17F)1||0.20 pg/mL||0.1 pg/mL||150 µL||150 µL|
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.